Laboratory markers of cardiovascular risk in pediatri SLE: The APPLE baseline cohort

Lupus

Volumn 19, Issue 11, 2010, Pages 1315-1325

  Ardoin, S P ^a   Schanberg, L E ^b   Sandborg, C ^c   Yow, E ^b   Barnhart, H X ^b   Mieszkalski, K L ^b   Ilowite, N T ^d   Von Scheven, E ^e   Eberhard, A ^f   Levy, D M ^g   Kimura, Y ^h   Silverman, E ⁱ   Bowyer, S L ^j   Punaro, L ^k   Singer, N G ^l   Sherry, D D ^m   McCurdy, D ⁿ   Klein Gitelman, M ^o   Wallace, C ^p   Silver, R ^q   Wagner Weiner, L ^r   Higgins, G C ^a   Brunner, H I ^s   Jung, L K ^t   Imundo, L ^g   Soep, J B ^u   Reed, A M ^v   more..

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f SCHNEIDER CHILDREN'S HOSPITAL   (United States)

^g NewYork Presbyterian Hospital   (United States)

^h HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

ⁱ HOSPITAL FOR SICK CHILDREN   (Canada)

^j INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k TEXAS SCOTTISH RITE HOSPITAL FOR CHILDREN   (United States)

^l UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^m CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o NORTHWESTERN UNIVERSITY   (United States)

^p SEATTLE CHILDREN S HOSPITAL   (United States)

^q MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^r UNIVERSITY OF CHICAGO   (United States)

^s CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^t CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^u CHILDREN S HOSPITAL   (United States)

^v MAYO CLINIC   (United States)

more..

Author keywords

atherosclerosis; cardiovascular; lipid; pediatric; SLE; systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; HYDROXYCHLOROQUINE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; METHOTREXATE; MULTIVITAMIN; MYCOPHENOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; TRIACYLGLYCEROL;

ADOLESCENT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHILD; CREATININE CLEARANCE; DISEASE ACTIVITY; FEMALE; HISPANIC; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINURIA; SYSTEMIC LUPUS ERYTHEMATOSUS; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN INTAKE;

ADOLESCENT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHILD; CHOLESTEROL; CROSS-SECTIONAL STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIPOPROTEIN(A); LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LUPUS ERYTHEMATOSUS, SYSTEMIC; PLACEBOS; RISK FACTORS; TRIGLYCERIDES; YOUNG ADULT;

EID: 78649747042     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203310373937     Document Type: Article

References (47)

1. Westerweel PE, Luyten RK, Koomans HA, Derksen RH, Verhaar MC Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum 2007 ; 56: 1384-1396.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001 ; 285: 2486-2497.
3. Petri M., Perez-Gutthann S., Spence D., Hochberg MC Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992 ; 93: 513-519.
4. Ilowite NT, Samuel P., Ginzler E., Jacobson MS Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum 1988 ; 31: 859-863.
5. Kashef S., Ghaedian MM, Rajaee A., Ghaderi A. Dyslipoproteinemia during the active course of systemic lupus erythematosus in association with anti-double-stranded DNA (anti-dsDNA) antibodies. Rheumatol Int 2007 ; 27: 235-241.
6. Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003 ; 290: 898-904.
7. Bassuk SS, Rifai N., Ridker PM High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol 2004 ; 29: 439-493. (Pubitemid 39055635)
8. Toloza SM, Uribe AG, McGwin Jr G., et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004 ; 50: 3947-3957.
9. Bowser CS, Kumar S., Salciccioli L., et al. Absence of Chlamydia pneumoniae and signs of atherosclerotic cardiovascular disease in adolescents with systemic lupus erythematosus. Pediatr Cardiol 2008 ; 29: 545-551.
10. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003 ; 107: 499-511.
11. Craig WY, Neveux LM, Palomaki GE, Cleveland MM, Haddow JE Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem 1998 ; 44: 2301-2306.
12. Smolders B., Lemmens R., Thijs V. Lipoprotein (a) and stroke: a meta-analysis of observational studies. Stroke 2007 ; 38: 1959-1966.
13. McCormack PL, Keating GM Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia. Drugs 2005 ; 65: 2719-2740.
14. Sari RA, Polat MF, Taysi S., Bakan E., Capoglu I. Serum lipoprotein(a) level and its clinical significance in patients with systemic lupus erythematosus. Clin Rheumatol 2002 ; 21: 520-524.
15. Soep JB, Mietus-Snyder M., Malloy MJ, Witztum JL, von Scheven E. Assessment of atherosclerotic risk factors and endothelial function in children and young adults with pediatric-onset systemic lupus erythematosus. Arthritis Rheum 2004 ; 51: 451-457.
16. Schanberg LE, Sandborg C., Barnhart HX, et al. Premature atherosclerosis in pediatric systemic lupus erythematosus: Risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. Arthritis Rheum 2009 ; 60: 1496-1507.
17. Wierzbicki AS Homocysteine and cardiovascular disease: a review of the evidence. Diab Vasc Dis Res 2007 ; 4: 143-150.
18. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002 ; 288: 2015-2022.
19. Lonn E., Yusuf S., Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006 ; 354: 1567-1577.
20. Pieretti J., Roman MJ, Devereux RB, et al. Systemic lupus erythematosus predicts increased left ventricular mass. Circulation 2007 ; 116: 419-426.
21. Tso TK, Huang HY, Chang CK, Huang WN A positive correlation between homocysteine and brachial-ankle pulse wave velocity in patients with systemic lupus erythematosus. Clin Rheumatol 2006 ; 25: 285-290.
22. on Feldt JM, Scalzi LV, Cucchiara AJ, et al. Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus. Arthritis Rheum 2006 ; 54: 2220-2227.
23. Roman MJ, Shanker BA, Davis A., et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003 ; 349: 2399-2406.
24. Hochberg MC Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997 ; 40: 1725.
25. Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005 ; 142: 953-962.
26. Gladman D., Ginzler E., Goldsmith C., et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996 ; 39: 363-369.
27. Schwartz GJ, Haycock GB, Edelmann Jr CM, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976 ; 58: 259-263.
28. Friedewald WT, Levy RI, Fredrickson DS Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972 ; 18: 499-502.
29. Cleveland WS Robust locally weighted regression and smoothing scatterplots. J Amer Statistical Assoc 1979 ; 74: 829.
30. National Cholesterol Education Program (NCEP). highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 1992 ; 89: 495-501.
31. Obisesan TO, Aliyu MH, Adediran AS, Bond V., Maxwell CJ, Rotimi CN Correlates of serum lipoprotein (A) in children and adolescents in the United States. The third National Health Nutrition and Examination Survey (NHANES-III). Lipids Health Dis 2004 ; 3: 29.
32. Ford ES, Giles WH, Myers GL, Rifai N., Ridker PM, Mannino DM C-reactive protein concentration distribution among US children and young adults: findings from the National Health and Nutrition Examination Survey, 1999-2000. Clin Chem 2003 ; 49: 1353-1357.
33. Kavanaugh A., Adams-Huet B., Jain R., Denke M., McFarlin J. Hydroxychloroquine Effects on Lipoprotein Profiles (the HELP trial): A Double-Blind, Randomized, Placebo-Controlled, Pilot Study In Patients With Systemic Lupus Erythematosus. J Clin Rheumatol 1997 ; 3: 3-8.
34. Ilowite NT, Copperman N., Leicht T., Kwong T., Jacobson MS Effects of dietary modification and fish oil supplementation on dyslipoproteinemia in pediatric systemic lupus erythematosus. J Rheumatol 1995 ; 22: 1347-1351.
35. Tyrrell PN, Beyene J., Benseler SM, Sarkissian T., Silverman ED Predictors of lipid abnormalities in children with new-onset systemic lupus erythematosus. J Rheumatol 2007 ; 34: 2112-2119.
36. Hodis HN, Quismorio Jr FP, Wickham E., Blankenhorn DH The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. J Rheumatol 1993 ; 20: 661-665.
37. Bertoli AM, Vila LM, Reveille JD, Alarcon GS LUMINA Study Group. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): LXI. Value of C-reactive protein as a marker of disease activity and damage. J Rheumatol 2008 ; 35: 2355-2358.
38. Lee SS, Singh S., Magder LS, Petri M. Predictors of high sensitivity C-reactive protein levels in patients with systemic lupus erythematosus. Lupus 2008 ; 17: 114-123.
39. Inoue T., Kanayama Y., Katoh N., et al. Significance of C-reactive protein elevation in the pretreatment stage of systemic lupus erythematosus. Scand J Rheumatol 1981 ; 10: 222-224.
40. Bertouch JV, Roberts-Thompson PJ, Feng PH, Bradley J. C-reactive protein and serological indices of disease activity in systemic lupus erythematosus. Ann Rheum Dis 1983 ; 42: 655-658.
41. Linares LF, Gomez-Reino JJ, Carreira PE, Morillas L., Ibero I. C-reactive protein (CRP) levels in systemic lupus erythematosus (SLE). Clin Rheumatol 1986 ; 5: 66-69.
42. Suh CH, Chun HY, Ye YM, Park HS Unresponsiveness of C-reactive protein in the non-infectious inflammation of systemic lupus erythematosus is associated with interleukin 6. Clin Immunol 2006 ; 119: 291-296.
43. Shoenfeld Y., Szyper-Kravitz M., Witte T., et al. Autoantibodies against protective molecules-C1q, C-reactive protein, serum amyloid P, mannose-binding lectin, and apolipoprotein A1: prevalence in systemic lupus erythematosus. Ann N Y Acad Sci 2007 ; 1108: 227-239.
44. Tomaszewski M., Charchar FJ, Maric C., et al. Glomerular hyper-filtration: a new marker of metabolic risk. Kidney Int 2007 ; 71: 816-821.
45. Seshadri N., Messerli AW, Acharya N., et al. Relation of homocysteine and C-reactive protein to urinary albumin loss. Am J Cardiol 2004 ; 93: 926-928.
46. Vermeulen EG, Rauwerda JA, van den Berg M., et al. Homocysteine-lowering treatment with folic acid plus vitamin B6 lowers urinary albumin excretion but not plasma markers of endothelial function or C-reactive protein: further analysis of secondary end-points of a randomized clinical trial. Eur J Clin Invest 2003 ; 33: 209-215.
47. Mann JF, Gerstein HC, Dulau-Florea I., Lonn E. Cardiovascular risk in patients with mild renal insufficiency. Kidney Int Suppl 2003 ; (84). S192-6.